168 related articles for article (PubMed ID: 15534881)
1. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
Gamis AS
Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
[TBL] [Abstract][Full Text] [Related]
2. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
3. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
5. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
[TBL] [Abstract][Full Text] [Related]
6. Down syndrome, drug metabolism and chromosome 21.
Taub JW; Ge Y
Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
[TBL] [Abstract][Full Text] [Related]
7. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
[TBL] [Abstract][Full Text] [Related]
8. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.
Bassal M; La MK; Whitlock JA; Sather HN; Heerema NA; Gaynon PS; Stork LC
Pediatr Blood Cancer; 2005 Jan; 44(1):21-8. PubMed ID: 15368546
[TBL] [Abstract][Full Text] [Related]
9. Optimizing therapy for myeloid disorders of Down syndrome.
Webb DK
Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
[TBL] [Abstract][Full Text] [Related]
10. Treatment of childhood acute myeloid leukemia.
ter Bals E; Kaspers GJ
Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
[TBL] [Abstract][Full Text] [Related]
11. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
12. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
13. A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.
Tigay JH
J Pediatr Oncol Nurs; 2009; 26(6):362-8. PubMed ID: 20032297
[TBL] [Abstract][Full Text] [Related]
14. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
16. Down syndrome and acute lymphoblastic leukaemia.
Whitlock JA
Br J Haematol; 2006 Dec; 135(5):595-602. PubMed ID: 17054672
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging strategies for the management of acute myeloid leukemia in the elderly.
Laubach J; Rao AV
Oncologist; 2008 Oct; 13(10):1097-108. PubMed ID: 18922830
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Ravindranath Y; Abella E; Krischer JP; Wiley J; Inoue S; Harris M; Chauvenet A; Alvarado CS; Dubowy R; Ritchey AK
Blood; 1992 Nov; 80(9):2210-4. PubMed ID: 1384797
[TBL] [Abstract][Full Text] [Related]
19. Reproductive history, infertility treatment, and the risk of acute leukemia in children with down syndrome: a report from the Children's Oncology Group.
Puumala SE; Ross JA; Olshan AF; Robison LL; Smith FO; Spector LG
Cancer; 2007 Nov; 110(9):2067-74. PubMed ID: 17849462
[TBL] [Abstract][Full Text] [Related]
20. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
